WO2008078715A1 - Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient - Google Patents

Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient Download PDF

Info

Publication number
WO2008078715A1
WO2008078715A1 PCT/JP2007/074751 JP2007074751W WO2008078715A1 WO 2008078715 A1 WO2008078715 A1 WO 2008078715A1 JP 2007074751 W JP2007074751 W JP 2007074751W WO 2008078715 A1 WO2008078715 A1 WO 2008078715A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
inflammatory myopathy
antagonist
active ingredient
inflammatory
Prior art date
Application number
PCT/JP2007/074751
Other languages
French (fr)
Japanese (ja)
Inventor
Hitoshi Kohsaka
Nobuyuki Miyasaka
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
National University Corporation Tokyo Medical And Dental University
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39562504&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008078715(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha, National University Corporation Tokyo Medical And Dental University, Riken filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of WO2008078715A1 publication Critical patent/WO2008078715A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Abstract

It is intended to provide an excellent therapeutic agent for inflammatory myopathy which can significantly suppress symptoms of inflammatory myopathy such as abnormal inflammatory cell infiltration in muscle fibers and does not have disadvantages of conventional drugs such as a general decrease in immunocompetence. That is, the invention relates to a therapeutic agent for inflammatory myopathy characterized by containing IL-6 antagonist as an active ingredient. In the therapeutic agent for inflammatory myopathy, the IL-6 antagonist is preferably an antibody against IL-6 receptor, a monoclonal antibody or the like.
PCT/JP2007/074751 2006-12-27 2007-12-21 Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient WO2008078715A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006351695A JP2010095445A (en) 2006-12-27 2006-12-27 Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient
JP2006-351695 2006-12-27

Publications (1)

Publication Number Publication Date
WO2008078715A1 true WO2008078715A1 (en) 2008-07-03

Family

ID=39562504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074751 WO2008078715A1 (en) 2006-12-27 2007-12-21 Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient

Country Status (5)

Country Link
JP (1) JP2010095445A (en)
AR (1) AR064538A1 (en)
CL (1) CL2007003817A1 (en)
PE (1) PE20081547A1 (en)
WO (1) WO2008078715A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
US8568720B2 (en) 2007-12-27 2013-10-29 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US8580264B2 (en) 2010-11-08 2013-11-12 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody
US8709409B2 (en) 2003-04-28 2014-04-29 Chugai Seiyaku Kabushiki Kaisha Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate
US8840884B2 (en) 2002-02-14 2014-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US9017677B2 (en) 1997-03-21 2015-04-28 Chugai Seiyaku Kabushiki Kaisha Methods of treating a disease mediated by sensitized T cells
US9255145B2 (en) 2001-04-02 2016-02-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US10168326B2 (en) 2013-07-04 2019-01-01 F. Hoffmann-La Roche Inc. Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
US10501769B2 (en) 2009-10-26 2019-12-10 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899902A (en) * 1994-09-30 1996-04-16 Chugai Pharmaceut Co Ltd Immature type myeloma cell treating agent containing il--6 receptor as active ingredient
JPH08208514A (en) * 1994-10-07 1996-08-13 Chugai Pharmaceut Co Ltd Chronic articular rheumatism-treating medicine containing il-6 antagonist as active ingredient
JPH10324639A (en) * 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Preventing and therapeutic agent for disease associated with sensitized t cell containing il-6 antagonist as active ingredient
WO1999047170A1 (en) * 1998-03-17 1999-09-23 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
WO2000010607A1 (en) * 1998-08-24 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for pancreatitis containing il-6 antagonists as the active ingredient
WO2002080969A1 (en) * 2001-04-02 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Remedies for infant chronic arthritis-relating diseases
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
WO2005061000A1 (en) * 2003-12-19 2005-07-07 Chugai Seiyaku Kabushiki Kaisha Remedy for angitis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899902A (en) * 1994-09-30 1996-04-16 Chugai Pharmaceut Co Ltd Immature type myeloma cell treating agent containing il--6 receptor as active ingredient
JPH08208514A (en) * 1994-10-07 1996-08-13 Chugai Pharmaceut Co Ltd Chronic articular rheumatism-treating medicine containing il-6 antagonist as active ingredient
JPH10324639A (en) * 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Preventing and therapeutic agent for disease associated with sensitized t cell containing il-6 antagonist as active ingredient
WO1999047170A1 (en) * 1998-03-17 1999-09-23 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
WO2000010607A1 (en) * 1998-08-24 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for pancreatitis containing il-6 antagonists as the active ingredient
WO2002080969A1 (en) * 2001-04-02 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Remedies for infant chronic arthritis-relating diseases
WO2004039826A1 (en) * 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
WO2005061000A1 (en) * 2003-12-19 2005-07-07 Chugai Seiyaku Kabushiki Kaisha Remedy for angitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCUDERI F. ET AL.: "IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis", JOURNAL OF NEUROIMMUNOLOGY, vol. 176, July 2006 (2006-07-01), pages 9 - 15, XP025039292, DOI: doi:10.1016/j.jneuroim.2006.03.026 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017677B2 (en) 1997-03-21 2015-04-28 Chugai Seiyaku Kabushiki Kaisha Methods of treating a disease mediated by sensitized T cells
US9255145B2 (en) 2001-04-02 2016-02-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US8840884B2 (en) 2002-02-14 2014-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US9051384B2 (en) 2002-02-14 2015-06-09 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
US10744201B2 (en) 2003-04-28 2020-08-18 Chugai Seiyaku Kabushiki Kaisha Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate
US8709409B2 (en) 2003-04-28 2014-04-29 Chugai Seiyaku Kabushiki Kaisha Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate
US9902777B2 (en) 2004-03-24 2018-02-27 Chugai Seiyaku Kabushiki Kaisha Methods for producing subtypes of humanized antibody against interleukin-6 receptor
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
US8734800B2 (en) 2004-03-24 2014-05-27 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
US11008394B2 (en) 2007-12-27 2021-05-18 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US8568720B2 (en) 2007-12-27 2013-10-29 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US11767363B2 (en) 2007-12-27 2023-09-26 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US11584798B2 (en) 2007-12-27 2023-02-21 Hoffmann-La Roche Inc. High concentration antibody-containing liquid formulation
US11359026B2 (en) 2007-12-27 2022-06-14 Chugai Seiyaku Kabushiki Kaisha High concentration antibody-containing liquid formulation
US10501769B2 (en) 2009-10-26 2019-12-10 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11021728B2 (en) 2009-10-26 2021-06-01 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11136610B2 (en) 2009-10-26 2021-10-05 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11377678B2 (en) 2009-10-26 2022-07-05 Hoffman-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US8580264B2 (en) 2010-11-08 2013-11-12 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody
US10874677B2 (en) 2010-11-08 2020-12-29 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US9750752B2 (en) 2010-11-08 2017-09-05 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US10231981B2 (en) 2010-11-08 2019-03-19 Chugai Seiyaku Kabushiki Kaisha Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
US11622969B2 (en) 2010-11-08 2023-04-11 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US11667720B1 (en) 2010-11-08 2023-06-06 Hoffmann-La Roche Inc. Subcutaneously administered anti-IL-6 receptor antibody
US9539263B2 (en) 2010-11-08 2017-01-10 Genentech, Inc. Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
US10761091B2 (en) 2013-07-04 2020-09-01 Hoffmann-La Roche, Inc. Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
US10168326B2 (en) 2013-07-04 2019-01-01 F. Hoffmann-La Roche Inc. Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Also Published As

Publication number Publication date
JP2010095445A (en) 2010-04-30
CL2007003817A1 (en) 2008-06-27
AR064538A1 (en) 2009-04-08
PE20081547A1 (en) 2009-01-18

Similar Documents

Publication Publication Date Title
WO2008078715A1 (en) Therapeutic agent for inflammatory myopathy containing il-6 antagonist as active ingredient
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
IL193444A (en) Isolated, cross-reactive monoclonal antibody that binds both il-17a and il-17f and isolated antisera containing it, a diagnostic kit comprising it, a pharmaceutical composition comprising it and uses thereof as a medicament for the treatment or prevention of inflammation or an inflammatory disease
WO2007119214A3 (en) Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2012059598A3 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008057579A3 (en) Dosage forms and co-administration of an opioid agonist and an opioid antagonist
EA201001253A1 (en) N, N-DESIGNED AMINOALKYLBIPHENYLES AS ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D
WO2007050802A3 (en) Novel opioid antagonists
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
WO2008128126A8 (en) Compositions and methods for prophylaxis and treatment of addictions
EA201390977A1 (en) COMBINATION OF OPIOID RECEPTOR AGONIST AND OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF PARKINSON'S Disease
WO2011004028A3 (en) Tlr3 binding agents
NO20085051L (en) Treatment of gastrointestinal disorders with CGRP antagonists
MY157716A (en) Solid dosage form of olmesartan medoxomil and amlodipine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859981

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07859981

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP